| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 3715 | 2020 |
| Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1836, 2020 | 2272 | 2020 |
| 2011 update of the drug resistance mutations in HIV-1 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ... Topics in antiviral medicine 19 (4), 156, 2011 | 1214 | 2011 |
| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1003 | 2021 |
| 2015 update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Top Antivir Med 23 (4), 132-41, 2015 | 889* | 2015 |
| Special contribution 2014 Update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Topics in antiviral medicine 22 (3), 642, 2014 | 889* | 2014 |
| Special contribution 2014 Update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Topics in antiviral medicine 22 (3), 642, 2014 | 889* | 2014 |
| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ... Nature medicine 16 (4), 460-465, 2010 | 613 | 2010 |
| Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a … L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ... The Lancet infectious diseases 11 (5), 363-371, 2011 | 421 | 2011 |
| Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis JZ Li, R Paredes, HJ Ribaudo, ES Svarovskaia, KJ Metzner, MJ Kozal, ... Jama 305 (13), 1327-1335, 2011 | 380 | 2011 |
| Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population AJ Rodger, R Lodwick, M Schechter, S Deeks, J Amin, R Gilson, ... Aids 27 (6), 973-979, 2013 | 371 | 2013 |
| Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy A Tuldrà, CR Fumaz, MJ Ferrer, R Bayés, A Arnó, M Balagué, A Bonjoch, ... Journal of acquired immune deficiency syndromes (1999) 25 (3), 221-228, 2000 | 343 | 2000 |
| Update of the drug resistance mutations in HIV-1: March 2013 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ... Topics in antiviral medicine 21 (1), 6, 2013 | 315 | 2013 |
| Gut microbiota linked to sexual preference and HIV infection M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ... EBioMedicine 5, 135-146, 2016 | 304 | 2016 |
| Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study R Paredes, A Mocroft, O Kirk, A Lazzarin, SE Barton, J Van Lunzen, ... Archives of internal medicine 160 (8), 1123-1132, 2000 | 292 | 2000 |
| Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo AMN Tsibris, B Korber, R Arnaout, C Russ, CC Lo, T Leitner, B Gaschen, ... PloS one 4 (5), e5683, 2009 | 252 | 2009 |
| Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression L Ruiz, J Martinez-Picado, J Romeu, R Paredes, MK Zayat, S Marfil, ... Aids 14 (4), 397-403, 2000 | 249 | 2000 |
| Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure R Paredes, CM Lalama, HJ Ribaudo, BR Schackman, C Shikuma, ... The Journal of infectious diseases 201 (5), 662-671, 2010 | 229 | 2010 |
| Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and … E Negredo, L Cruz, R Paredes, L Ruiz, CR Fumaz, A Bonjoch, S Gel, ... Clinical infectious diseases 34 (4), 504-510, 2002 | 222 | 2002 |
| Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a … L Ruiz, E Negredo, P Domingo, R Paredes, E Francia, M Balagué, S Gel, ... Journal of acquired immune deficiency syndromes (1999) 27 (3), 229-236, 2001 | 213 | 2001 |
Bonaventura ClotetDirector irsiCaixa AIDS Research InstituteVerified email at irsicaixa.es
